Skip to main content
SpringerLink
Log in

Management of human immunodeficiency virus-associated lymphomas

  • Chapter
  • First Online:
Handbook of Lymphoma

Abstract

Human immunodeficiency virus (HIV) infection is associated with a variety of malignancies including acquired immune deficiency syndrome (AIDS)-defining and non-AIDS-defining lymphomas. Collectively, they may be referred to as HIV-associated lymphomas. AIDS-defining non-Hodgkin lymphomas (NHL) include diffuse large B-cell lymphoma (DLBCL), Burkitt’s lymphoma, primary central nervous system (CNS) lymphoma, and less commonly primary effusion lymphoma and plasmablastic lymphoma. Approximately 10 % of HIV patients will develop a NHL. Non-AIDS-defining lymphomas, which have an increased prevalence in HIV-infected individuals, include Hodgkin lymphoma (HL). The risk of developing a HIV-associated lymphoma correlates directly with the degree of immune dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122:3251-3262.

    Google Scholar 

  2. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.

    Google Scholar 

  3. Lim ST, Karim R, Tulpule A, Nathwani BN, Levine AM. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol. 2005;23:8477-82.

    Google Scholar 

  4. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1641-1648.

    Google Scholar 

  5. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538-1543.

    Google Scholar 

  6. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:4123-8.

    Google Scholar 

  7. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115:3008-3016.

    Google Scholar 

  8. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105:1891-1897.

    Google Scholar 

  9. Levine AM, Noy A, Lee JY, et al. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2013;31:58-64.

    Google Scholar 

  10. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and shortcourse EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115:3017-3024.

    Google Scholar 

  11. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113:3896-3902.

    Google Scholar 

  12. Savage KJ, Zeynalova S, Kansara RR, et al. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Blood. 2014;124:394.

    Google Scholar 

  13. Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol. 2012;23:1267-1273.

    Google Scholar 

  14. Galicier L, Fieschi C, Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood. 2007;110:2846-2854.

    Google Scholar 

  15. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003;98:1196-1205.

    Google Scholar 

  16. Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s lymphoma. AIDS. 2010;24:851-856.

    Google Scholar 

  17. Xicoy B, Ribera JM, Muller M, et al. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. Leuk Lymphoma. 2014;55:2341-2348.

    Google Scholar 

  18. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915-1925.

    Google Scholar 

  19. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23:4372-4380.

    Google Scholar 

  20. Bhatt S, Ashlock BM, Natkunam Y, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013;122:1233-1242.

    Google Scholar 

  21. Bryant A, Milliken S. Successful reduced-intensity conditioning allogeneic HSCT for HIVrelated primary effusion lymphoma. Biol Blood Marrow Transplant. 2008;14:601-602.

    Google Scholar 

  22. Waddington TW, Aboulafia DM. Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. AIDS Patient Care STDs. 2004;18:67-73.

    Google Scholar 

  23. Pereira R, Carvalho J, Patricio C, Farinha P. Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient. BMJ Case Rep. 2014;2014.

    Google Scholar 

  24. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14:59-66.

    Google Scholar 

  25. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognosticfactors. Blood. 2009;114:1306-1313.

    Google Scholar 

  26. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica. 2004;89:1100-1108.

    Google Scholar 

  27. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105:874-878.

    Google Scholar 

  28. Balsalobre P, Diez-Martin JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol. 2009;27:2192-2198.

    Google Scholar 

  29. Diez-Martin JL, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113:6011-6014.

    Google Scholar 

  30. Kasamon YL, Ambinder RF. AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005;19:665-687.

    Google Scholar 

  31. Cinque P, Brytting M, Vago L, et al. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet. 1993;342: 398-401.

    Google Scholar 

  32. Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS. 1997;11:1725-1730.

    Google Scholar 

  33. Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004;100:2627-2536.

    Google Scholar 

  34. Gastaldi R, Martino P, Gentile G, et al. Hodgkin’s disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor. Ann Oncol. 2002;13:1158-1160.

    Google Scholar 

  35. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol. 2003;14:1562-1569.

    Google Scholar 

  36. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100:1984-1988.

    Google Scholar 

  37. Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica. 2007;92: 191-198.

    Google Scholar 

  38. Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30:4111-4116.

    Google Scholar 

  39. Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30:4117-4123.

    Google Scholar 

  40. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:640-652.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Connie Batlevi

Authors
  1. Connie Batlevi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, New York, New York, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Batlevi, C. (2016). Management of human immunodeficiency virus-associated lymphomas. In: Younes, A. (eds) Handbook of Lymphoma. Adis, Cham. https://doi.org/10.1007/978-3-319-08467-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08467-1_9

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08466-4

  • Online ISBN: 978-3-319-08467-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation